Article
Biochemistry & Molecular Biology
Seong A. Kim, Seohyun Kim, Gi Beom Kim, Jiyoung Goo, Nayeon Kim, Yeram Lee, Gi-Hoon Nam, Seungho Lim, Taeerk Kim, Ki Hwan Chang, Tae Gyu Lee, In-San Kim, Eun Jung Lee
Summary: In this study, a multivalent SARS-CoV-2 vaccine was developed using ferritin nanocages, which successfully induced CD4(+) and CD8(+) T cell and B-cell immunity in vivo and generated a more consistent antibody response against the B.1.351 and B.1.429 variants compared to a monovalent vaccine. This suggests that the proposed ferritin-nanocage-based multivalent vaccine platform provides strong protection against emerging SARS-CoV-2 variants of concern.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Yongbo Qiao, Shuang Li, Shenghui Jin, Yi Pan, Yuhua Shi, Wei Kong, Yaming Shan
Summary: This study developed nanoparticle vaccines based on the HA stem of influenza virus, showing that CDh-based nanovaccine induced robust immune responses and complete protection in mice against H3N2 virus challenge, while Ah-f group had no remarkable effects. Conjugating epitopes with ferritin NPs may be a potential platform for vaccines against other infectious viruses, such as SARS-COV-2.
Article
Immunology
Li Chen, Haiwei Zhang, Moxuan Li, Bihao Wu, Zhe Zhang, Rui Gong
Summary: In this study, researchers developed an intranasal vaccine using a fusion of SARS-CoV-2 RBD and antibody Fc fragment. This vaccine could induce strong humoral immune responses and establish mucosal immunity in the respiratory tract. It also showed effectiveness in neutralizing various SARS-CoV-2 variants, including the Omicron variant. The findings suggest that this mucosal vaccine has the potential to reduce the risk of SARS-CoV-2 infection.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Xingjian Liu, Haozhi Song, Jianmin Jiang, Xintao Gao, Yongzhu Yi, Yuting Shang, Jialei Li, Dan Li, Zhen Zeng, Yinu Li, Zhifang Zhang
Summary: In this study, preparation strategies for SARS-CoV-2 Spike protein receptor-binding domain, S1 region, and ectodomain trimer nanoparticles were designed using ferritin nanoparticle self-assembly technology. The results showed that the nanoparticle vaccine prepared using this strategy could induce immune responses when administered via both the subcutaneous administration and oral routes. These ferritin-based nanoparticle vaccines offer an easy-to-use and low-cost oral immunization strategy for areas with limited resources.
PROCESS BIOCHEMISTRY
(2023)
Article
Multidisciplinary Sciences
Tianyang Mao, Benjamin Israelow, Mario A. Pena-Hernandez, Alexandra Suberi, Liqun Zhou, Sophia Luyten, Melanie Reschke, Huiping Dong, Robert J. Homer, W. Mark Saltzman, Akiko Iwasaki
Summary: This study developed a vaccine strategy called prime and spike, which activates mucosal immune memory within the respiratory tract and induces strong immune responses. It enhances both systemic and local immunity against SARS-CoV-2, and provides full protection against lethal infection in partially immune mice.
Article
Cell Biology
Ching-Lin Hsieh, Anne P. Werner, Sarah R. Leist, Laura J. Stevens, Ester Falconer, Jory A. Goldsmith, Chia-Wei Chou, Olubukola M. Abiona, Ande West, Kathryn Westendorf, Krithika Muthuraman, Ethan J. Fritch, Kenneth H. Dinnon, Alexandra Schafer, Mark R. Denison, James D. Chappell, Ralph S. Baric, Barney S. Graham, Kizzmekia S. Corbett, Jason S. McLellan
Summary: This study developed stabilized stem (SS) antigens by removing the S1 subunit from the Middle East respiratory syndrome (MERS)-CoV spike (S) glycoprotein using structure-guided protein engineering. Vaccination with MERS SS elicited cross-reactive b-CoV antibody responses and protected mice against lethal MERS-CoV challenge. The discovery of a panel of cross-reactive monoclonal antibodies, among which IgG22 showed high affinity binding to both MERS-CoV and severe acute respiratory syndrome (SARS)-CoV-2 S proteins, indicates the potential for cross-reactive CoV antibodies.
Article
Immunology
Qinhai Ma, Runfeng Li, Jianmin Guo, Man Li, Lin Ma, Jun Dai, Yongxia Shi, Jinlong Dai, Yuankeng Huang, Cailing Dai, Weiqi Pan, Huiling Zhong, Hong Zhang, Jian Wen, Haoting Zhao, Linping Wu, Wei Yang, Biliang Zhang, Zifeng Yang
Summary: RBMRNA-176 is a broad-spectrum and protective vaccine candidate for COVID-19 that can generate high titer antibodies and neutralize different variants of SARS-CoV-2. It also demonstrates effective control of viral replication and lung injury in animal studies.
Article
Immunology
Kathryn McGuckin Wuertz, Erica K. Barkei, Wei-Hung Chen, Elizabeth J. Martinez, Ines Lakhal-Naouar, Linda L. Jagodzinski, Dominic Paquin-Proulx, Gregory D. Gromowski, Isabella Swafford, Akshaya Ganesh, Ming Dong, Xiankun Zeng, Paul Thomas, Rajeshwer S. Sankhala, Agnes Hajduczki, Caroline E. Peterson, Caitlin Kuklis, Sandrine Soman, Lindsay Wieczorek, Michelle Zemil, Alexander Anderson, Janice Darden, Heather Hernandez, Hannah Grove, Vincent Dussupt, Holly Hack, Rafael de la Barrera, Stasya Zarling, James F. Wood, Jeffrey W. Froude, Matthew Gagne, Amy R. Henry, Elham Bayat Mokhtari, Prakriti Mudvari, Shelly J. Krebs, Andrew S. Pekosz, Jeffrey R. Currier, Swagata Kar, Maciel Porto, Adrienne Winn, Kamil Radzyminski, Mark G. Lewis, Sandhya Vasan, Mehul Suthar, Victoria R. Polonis, Gary R. Matyas, Eli A. Boritz, Daniel C. Douek, Robert A. Seder, Sharon P. Daye, Mangala Rao, Sheila A. Peel, M. Gordon Joyce, Diane L. Bolton, Nelson L. Michael, Kayvon Modjarrad
Summary: The study demonstrates that the use of SpFN-ALFQ vaccine provides protection against SARS-CoV-2-induced disease and viral replication, reducing lung pathology and viral burden.
Article
Chemistry, Multidisciplinary
Xiantao Zhang, Shijian Wu, Jie Liu, Ran Chen, Yongli Zhang, Yingtong Lin, Zhihui Xi, Jieyi Deng, Zeyu Pu, Chaofeng Liang, Jinzhu Feng, Rong Li, Keming Lin, Mo Zhou, Yingying Liu, Xu Zhang, Bingfeng Liu, Yiwen Zhang, Xin He, Hui Zhang
Summary: To prevent the infection of SARS-CoV-2, a vaccine targeting multiple sublineages of the virus in the upper respiratory tract has been developed. This vaccine induces specific neutralizing antibodies and strong cellular immune responses. It exhibits broad cross-protective activity and can elicit robust mucosal immune responses through intranasal delivery, providing full protection.
Article
Immunology
Antonella Scaglione, Silvana Opp, Alicia Hurtado, Ziyan Lin, Christine Pampeno, Maria G. Noval, Sara A. Thannickal, Kenneth A. Stapleford, Daniel Meruelo
Summary: This study introduces a novel and highly effective vaccine approach that provides long-term protective immunity by activating T cells. The vaccine shows strong immune protection against coronavirus infection in transgenic mice. The results suggest that this vaccine may be effective against challenging variants and could serve as a platform for developing a broader spectrum pancoronavirus vaccine.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Xiaoyan Pan, Jian Shi, Xue Hu, Yan Wu, Liang Zeng, Yanfeng Yao, Weijuan Shang, Kunpeng Liu, Ge Gao, Weiwei Guo, Yun Peng, Shaohong Chen, Xiaoxiao Gao, Cheng Peng, Juhong Rao, Jiaxuan Zhao, Cheng Gong, Hui Zhou, Yudong Lu, Zili Wang, Xiliang Hu, WenJuan Cong, Lijuan Fang, Yongxiang Yan, Jing Zhang, Hui Xiong, Jizu Yi, Zhiming Yuan, Pengfei Zhou, Chao Shan, Gengfu Xiao
Summary: The novel SARS-CoV-2 vaccine candidate RBD dimer, formulated with aluminum adjuvant, demonstrated strong immune response in rodents and non-human primates, offering protection against SARS-CoV-2 infection. It also showed cross-neutralization activities to SARS-CoV-2 variants and can be produced in high yield without additional biosafety or special transport device supports, making it a potential safe, effective, and low-cost vaccine candidate.
Article
Multidisciplinary Sciences
Vincent Pavot, Catherine Berry, Michael Kishko, Natalie G. G. Anosova, Lu Li, Tim Tibbitts, Dean Huang, Alice Raillard, Sylviane Gautheron, Cindy Gutzeit, Marguerite Koutsoukos, Roman M. M. Chicz, Valerie Lecouturier
Summary: The rapid spread of the SARS-CoV-2 Omicron subvariants, despite booster vaccination, has raised concerns about vaccine durability. A monovalent Beta vaccine with AS03 adjuvant induces durable cross-neutralizing antibody responses against various SARS-CoV-2 variants, even 6 months post-booster. This study highlights the importance of developing vaccines that can induce robust and long-lasting immune responses against a broad spectrum of variants.
NATURE COMMUNICATIONS
(2023)
Article
Immunology
Qier Chen, Rong Li, Bolin Wu, Xu Zhang, Hui Zhang, Ran Chen
Summary: Dengue fever, caused by the dengue virus, is a global health threat. Developing a safe and effective vaccine is challenging due to antibody-dependent enhancement (ADE). Researchers have successfully developed a tetravalent nanoparticle vaccine that induces potent immune responses and protects against DENV-2 and DENV-3 challenges in mice.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Kyung Soo Park, Joseph D. Bazzill, Sejin Son, Jutaek Nam, Seung Won Shin, Lukasz J. Ochyl, Jeanne A. Stuckey, Jennifer L. Meagher, Louise Chang, Jun Song, David C. Montefiori, Celia C. LaBranche, Janet L. Smith, Jie Xu, James J. Moon
Summary: The study introduces a new lipid-based nanoparticle vaccine platform that effectively presents viral proteins to induce antibody responses and promotes dendritic cell uptake. Using this platform successfully induced neutralizing antibody responses against HIV-1 and SARS-CoV-2.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Biotechnology & Applied Microbiology
Shi-Jian Song, Heeyeon Kim, Eun Young Jang, Hyungmin Jeon, Hai-Ping Diao, Md Rezaul Islam Khan, Mi-Seon Lee, Young Jae Lee, Jeong-hyun Nam, Seong-Ryeol Kim, Young-Jin Kim, Eun-Ju Sohn, Inhwan Hwang, Jang-Hoon Choi
Summary: This study generated a candidate COVID-19 vaccine by expressing recombinant S proteins in tobacco, which induced immune responses and cross-neutralizing antibodies against multiple variants in mouse and knock-in mouse models.
PLANT BIOTECHNOLOGY JOURNAL
(2022)
Article
Biochemistry & Molecular Biology
Suzanne M. Scheaffer, Diana Lee, Bradley Whitener, Baoling Ying, Kai Wu, Chieh-Yu Liang, Hardik Jani, Philippa Martin, Nicholas J. Amato, Laura E. Avena, Daniela Montes Berrueta, Stephen D. Schmidt, Sijy O'Dell, Arshan Nasir, Gwo-Yu Chuang, Guillaume Stewart-Jones, Richard A. Koup, Nicole A. Doria-Rose, Andrea Carfi, Sayda M. Elbashir, Larissa B. Thackray, Darin K. Edwards, Michael S. Diamond
Summary: Bivalent vaccines induce broad immune responses against SARS-CoV-2 and its variants, offering a customizable approach to protect against COVID-19 as new strains emerge.
Article
Microbiology
Elizabeth E. Zumbrun, Chengzi I. Kaku, Lukas Dillinger, Samantha E. Zak, Ana I. Kuehne, Russel R. Bakken, Jeffrey W. Koehler, Korey L. Delp, Christopher P. Stefan, Raina Kumar, Jeffrey R. Kugelman, Alicia M. Moreau, Xiankun Zeng, John M. Dye, Andrew S. Herbert, Kristin Narayan, Laura M. Walker
Summary: Adintrevimab is an engineered human monoclonal antibody that can neutralize SARS-CoV-2 variants and other SARS-like coronaviruses. In animal models, a single prophylactic dose of adintrevimab provided protection against SARS-CoV-2 infection by reducing viral load, lung pathology, and replication in the respiratory tract.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Biochemistry & Molecular Biology
Vikas Chonira, Young D. Kwon, Jason Gorman, James Brett Case, Zhiqiang Ke, Rudo Simeon, Ryan G. Cosner, Darcy R. Harris, Adam S. Olia, Tyler Stephens, Lawrence Shapiro, Michael F. Bender, Hannah Boyd, I-Ting Teng, Yaroslav Tsybovsky, Florian Krammer, Ningyan Zhang, Michael S. Diamond, Peter D. Kwong, Zhiqiang An, Zhilei Chen
Summary: We report the engineering and selection of two synthetic proteins, FSR16m and FSR22, for the potential treatment of SARS-CoV-2 infection. These proteins exhibit broad-spectrum neutralization of SARS-CoV-2 strains and show promising results in mice, reducing viral burden and weight loss.
NATURE CHEMICAL BIOLOGY
(2023)
Review
Microbiology
Arthur S. Kim, Michael S. Diamond
Summary: This Review provides an overview of the global epidemics caused by arthropod-transmitted RNA viruses known as alphaviruses. It highlights the host factors required for alphavirus entry, the mechanisms by which protective antibodies inhibit alphavirus infection, and the progress of clinical evaluation of candidate vaccines focusing on humoral immunity.
NATURE REVIEWS MICROBIOLOGY
(2023)
Article
Immunology
Zhanna Shubin, Sherry Stanfield-Oakley, Jiraporn Puangkaew, Punnee Pitisutthithum, Sorachai Nitayaphan, Sanjay Gurunathan, Faruk Sinangil, Suwat Chariyalertsak, Nittaya Phanuphak, Julie A. Ake, Robert J. O'Connell, Sandhya Vasan, Siriwat Akapirat, Michael A. Eller, Guido Ferrari, Dominic Paquin-Proulx
Summary: A study found that an additional boost to the RV144 vaccine regimen can enhance Fc-mediated effector functions but does not significantly affect the durability of vaccine efficacy, with trogocytosis being the most durable.
Article
Plant Sciences
M. S. Nair, Y. Huang, M. Wang, P. J. Weathers
Summary: Artemisia annua L., with a history of over 2000 years, has been used to treat fever, a common symptom of many infectious diseases including viruses. This study aimed to test the efficacy of A. annua extracts against highly infectious omicron and its recent subvariants of the SARS-CoV-2 virus.
JOURNAL OF ETHNOPHARMACOLOGY
(2023)
Article
Virology
James D. Stamos, Mohammad Arif Rahman, Giacomo Gorini, Isabela Silva de Castro, Manuel Becerra-Flores, David J. Van Wazer, Kombo F. N'Guessan, Natasha M. Clark, Massimiliano Bissa, Anna Gutowska, Rosemarie D. Mason, Jiae Kim, Mangala Rao, Mario Roederer, Dominic Paquin-Proulx, David T. Evans, Claudia Cicala, James Arthos, Peter D. Kwong, Tongqing Zhou, Timothy Cardozo, Genoveffa Franchini
Summary: Studies have shown that the protection against SIV/SHIV acquisition provided by SIV/HIV V1 deletion-containing envelope immunogens delivered by the DNA/ALVAC vaccine platform requires multiple host responses. Anti-inflammatory macrophages, tolerogenic dendritic cells, and efferocytes are associated with a decreased risk of SIV/SHIV acquisition. Monoclonal antibodies NCI05 and NCI09, targeting the V2 region, have different antiviral functions, with NCI05 delaying SIVmac251 acquisition.
JOURNAL OF VIROLOGY
(2023)
Article
Cell Biology
Glennys Reynoso, David N. Gordon, Anurag Kalia, Cynthia C. Aguilar, Courtney S. Malo, Maya Aleshnick, Kimberly A. Dowd, Christian R. Cherry, John P. Shannon, Sophia M. Vrba, Autumn C. Holmes, Yael Alippe, Sonia Maciejewski, Kenichi Asano, Michael S. Diamond, Theodore C. Pierson, Heather D. Hickman
Summary: To understand the initial steps in Zika virus (ZIKV) transmission, researchers investigated the virus's movement from the skin to the lymph nodes. Contrary to previous beliefs, migratory immune cells were not necessary for the virus to reach the lymph nodes or the bloodstream. Instead, a specific subset of macrophages in the lymph nodes, called CD169+ macrophages, were found to be rapidly infected by ZIKV and release the virus to infect other lymph nodes. These findings improve our understanding of ZIKV dissemination and identify a potential target for antiviral intervention.
Article
Immunology
Mohammad Arif Rahman, Manuel Becerra-Flores, Yury Patskovsky, Isabela Silva de Castro, Massimiliano Bissa, Shraddha Basu, Xiaoying Shen, LaTonya D. Williams, Sarkis Sarkis, Kombo F. N'guessan, Celia LaBranche, Georgia D. Tomaras, Pyone Pyone Aye, Ronald Veazey, Dominic Paquin-Proulx, Mangala Rao, Genoveffa Franchini, Timothy Cardozo
Summary: Designed a unique HIV vaccine to reveal the immune factors that contribute to protection against HIV/SIV. It was found that certain specific immune responses have a significant impact on the protective effect. The study shows that viral spike B-cell epitopes can produce functional antibodies, although their efficacy in neutralization and protection against tier 1 virus is limited.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Microbiology
Samantha R. Mackin, Pritesh Desai, Bradley M. Whitener, Courtney E. Karl, Meizi Liu, Ralph S. Baric, Darin K. Edwards, Taras M. Chicz, Ryan P. McNamara, Galit Alter, Michael S. Diamond
Summary: Fc-Fc gamma receptor interactions and alveolar macrophages play a crucial role in controlling infection with SARS-CoV-2 variants in mice vaccinated with ancestral vaccines. While the spike protein antigenic changes in SARS-CoV-2 variants reduce the neutralizing efficiency of legacy vaccine-induced antibodies, vaccines like mRNA-1273 and BNT162b2 still protect against severe disease and death, indicating the involvement of other aspects of immunity in controlling lung infection. Antibodies elicited by vaccines can bind Fc gamma receptors and exert effector functions against SARS-CoV-2 variants, and this property is associated with improved clinical outcomes. However, the causal relationship between Fc effector functions and vaccine-induced protection against infection needs further investigation.
NATURE MICROBIOLOGY
(2023)
Article
Immunology
Shikha Shrivastava, Joshua M. Carmen, Zhongyan Lu, Shraddha Basu, Rajeshwer S. Sankhala, Wei-Hung Chen, Phuong Nguyen, William C. Chang, Jocelyn King, Courtney Corbitt, Sandra Mayer, Jessica S. Bolton, Alexander Anderson, Isabella Swafford, Guillermo D. Terriquez, Hung V. Trinh, Jiae Kim, Ousman Jobe, Dominic Paquin-Proulx, Gary R. Matyas, Gregory D. Gromowski, Jeffrey R. Currier, Elke Bergmann-Leitner, Kayvon Modjarrad, Nelson L. Michael, M. Gordon Joyce, Allison M. W. Malloy, Mangala Rao
Summary: This study demonstrates the impact of adjuvants on the development of Tfh and B cells, and their influence on antibody responses in mice vaccinated with SpFN adjuvanted with either ALFQ or AH. ALFQ vaccination resulted in increased size and frequency of GC B cells, higher frequency of IL-21-producing Tfh and GC B cells, and elicitation of robust cross-neutralizing antibodies against SARS-CoV-2 variants. No cross-neutralizing antibodies against Omicron were induced with AH. These findings highlight the importance of ALFQ in orchestrating early induction of antigen-specific Tfh and GC B cell responses and long-lived plasma cells in the bone marrow.
Article
Medicine, Research & Experimental
Margaret C. Costanzo, Dominic Paquin-Proulx, Alexandra Schuetz, Siriwat Akapirat, Zhanna Shubin, Dohoon Kim, Lindsay Wieczorek, Victoria R. Polonis, Hung V. Trinh, Mangala Rao, Hanna Anenia, Michael D. Barrera, Jacob Boeckelman, Barbara Nails, Pallavi Thapa, Michelle Zemil, Carlo Sacdalan, Eugene Kroon, Boot Kaewboon, Somporn Tipsuk, Surat Jongrakthaitae, Sanjay Gurunathan, Faruk Sinangil, Jerome H. Kim, Merlin L. Robb, Julie A. Ake, Robert J. O'Connell, Punnee Pitisutthithum, Sorachai Nitayaphan, Suwat Chariyalertsak, Michael A. Eller, Nittaya Phanuphak, Sandhya Vasan
Summary: The combination of ALVAC-HIV with AIDSVAX B/E significantly enhances cellular and humoral immune responses compared to the administration of AIDSVAX B/E alone, leading to increased efficacy in preventing HIV acquisition. This is evidenced by increased CD4+ HIV-specific T cell responses, polyfunctionality, and proliferation, as well as the identification of Env-specific plasmablasts and A244-specific memory B cells in the ALVAC-HIV group. Furthermore, plasma IgG binding to and avidity for HIV Env, as well as Fc-mediated effector functions, including antibody-dependent cellular cytotoxicity, NK cell activation, and trogocytosis, were significantly higher in participants who received ALVAC-HIV.
Article
Biochemical Research Methods
Matthew Creegan, Justin Degler, Dominic Paquin-Proulx, Michael A. Eller, Kawthar Machmach
Article
Multidisciplinary Sciences
Qian Wang, Yicheng Guo, Liyuan Liu, Logan T. Schwanz, Zhiteng Li, Manoj S. Nair, Jerren Ho, Richard M. Zhang, Sho Iketani, Jian Yu, Yiming Huang, Yiming Qu, Riccardo Valdez, Adam S. Lauring, Yaoxing Huang, Aubree Gordon, Harris H. Wang, Lihong Liu, David D. Ho
Summary: The BA.2.86 subvariant of SARS-CoV-2 was found to be no more resistant to human sera than the currently dominant XBB.1.5 and EG.5.1, but it had a remarkably higher receptor affinity.
Review
Virology
Mohammad Fereidouni, Dmitry A. Apanaskevich, David B. Pecor, Natalia Yu. Pshenichnaya, Gulzhan N. Abuova, Farida H. Tishkova, Yekaterina Bumburidi, Xiankun Zeng, Jens H. Kuhn, Maryam Keshtkar-Jahromi
Summary: This study summarizes the status of Crimean-Congo hemorrhagic fever (CCHF) in Central, Eastern, and South-eastern Asia. The risk and burden of CCHF were assessed based on case reports, antibody prevalence, and vector ticks isolation. The majority of cases were reported in Central Asia, while only China reported cases in Eastern Asia. No cases were reported in South-eastern Asia. Countries were classified into different levels based on evidence of CCHF, guiding the strengthening or establishment of CCHF surveillance systems.
